English

郭志云 副教授

生命科学与工程学院

+

个人信息

报考该导师

  • 学位:理学博士学位
  • 办公地址:西南交通大学九里校区3734
  • 邮箱:

个人简介

郭志云,男,山西大同人,四川大学生物治疗国家重点实验室博士毕业,宾夕法尼亚大学医学院博士后,西南交通大学生命科学与工程学院副教授,曾在军事医学科学院生物工程研究所从事研究工作。目前主要从事的领域为生物信息学与肿瘤分子生物学。团队致力于通过干湿结合的方法对肿瘤调控机制、抗肿瘤药物、肿瘤标志物等进行研究。研究兴趣包括:肿瘤生物信息学、抗肿瘤药物与标志物、基因测序、生物医疗健康大数据挖掘以及生物数据库的构建。目前以第一或通讯作者已发表30余篇SCI论文,获发明专利1项,软件著作权16项。现任Frontiers in Genetics等杂志编委、中国抗癌协会甲基化标志物专家委员会委员,四川省生物信息学会理事等职。


研究方向:

1、利用干(生物信息学与计算生物学)湿(分子生物学实验)手段研究调控元件在肿瘤中调控机制与分子机理。

2、肿瘤药物作用机制与肿瘤标志物,应用于肿瘤早期诊断与抗肿瘤药物研发

3、基于临床与高通量测序数据,对非编码RNA 在肿瘤调控中的机制与功能进行研究。

4、利用生物信息学与人工智能手段,对精准医疗与健康大数据挖掘、分析并进行网页数据库(Database)的开发。

5、分子模拟与药物设计


部分发表论文:

1. TengweiZhong, WenqingWang, HouyanLiu, MaolinZeng, XinyuZhao and ZhiyunGuo*, eccDNAAtlas: a comprehensive resource of eccDNA catalog, Briefings in Bioinformatics, 2023, 1–7   

2. Qingqing Huang, Zhengtang Tan, Yanjing Li, Wenzhu Wang, Mei Lang, Changying Li, Zhiyun Guo*, TFcancer: a manually curated database of transcription factors associated with human cancer. Bioinformatics, 2021, 37(22), 4288–4290.

2.      Mingming Qian§, Wenzhu Wang§, Yana Zhang, Yi Zhao, Huige Quan,Yuting Chen, Xinyue Dai and Zhiyun Guo*, Identification and characteristic analysis of enhancers across 13 major cancer types, Precision Clinical Medicine, 2021, 4(3), 204–208, https://doi.org/10.1093/pcmedi/pbab019

3.      Ran Kang, Zhengtang Tan, Mei Lang, Linqi Jin, Yin Zhang, Yiming Zhang, Tailin Guo, Zhiyun Guo*. EnhFFL: A database of enhancer mediated feed-forward loops for human and mouse. Precision Clinical Medicine, 2021, 4(2), 129–135, https://doi.org/10.1093/pcmedi/pbab006

4.      Fei Tang, Yin Zhang, Qing-Qing Huang, Ming-Ming Qian, Zhi-Xue Li, Yan-Jing Li, Bei-Ping Li, Zheng-Liang Qiu, Jun-Jie Yue, Zhi-Yun Guo* , Genome-Wide Identification and Analysis of Enhancer-Regulated microRNAs Across 31 Human Cancers. Frontiers in Genetics, 2020. 11: p. 644.

5.      Yin Zhang, Mingming Qian, Fei Tang, Qingqing Huang, Wenzhu Wang, Yanjing Li,Zhixue Li, Beiping Li, Zhengliang Qiu, Junjie Yue and Zhiyun Guo*, Identification and Analysis of p53-Regulated Enhancers in Hepatic Carcinoma. Frontiers in Bioengineering and Biotechnology, 2020. 8: p. 668.

6.      Ran Kang, Yiming Zhang, Qingqing Huang, Junhua Meng, Ruofan Ding, Yunjian Chang, Lili Xiong, Zhiyun Guo*, EnhancerDB: A Resource of Transcriptional Regulation in the Context of Enhancers, Database (Oxford). 2019.doi: 10.1093/database/bay141

7.      Liu W, Huai R, Zhang Y, Rao S, Xiong L, Ding R, Mao C, Zhao W, Hao T, Huang Q, Guo Z*.Down-regulation expression of TGFB2-AS1 inhibits the proliferation, migration, invasion and induces apoptosis in HepG2 cells. Genes Genomics. 2019 41(8):951-959

8.      Xiong LL#, Kang R, Ding RF, Kang WY, Zhang YM, Liu WR, Huang QQ, Meng JH, Guo ZY*, Genome-wide Identification and Characterization of Enhancers Across 10 Human Tissues, International Journal of Biological Sciences. 2018 Jul 27;14(10):1321-1332.

9.      Rao S#*, Ghani M#, Guo Z#, Deming Y, Wang K, Sims R, Mao C, Yao Y, Cruchaga C, Stephan DA, Rogaeva E. An APOE-independent cis-eSNP on chromosome 19q13.32 influences tau levels and late-onset Alzheimer's disease risk. Neurobiol Aging, 2018, S0197-4580(17)30424-4.

10.   Bi Z#, Liu W, Ding R, Wu Y, Dou R, Zhang W, Yuan X, Liu X, Xiong L, Guo Z*, Mao C*.A novel peptide, 9R-P201, strongly inhibits the viability, proliferation and migration of liver cancer HepG2 cells and induces apoptosis by down-regulation of FoxM1 expression. European Journal of Pharmacology. 2017, 796:175-189

11.   Yiming Zhang#, Ran Kang, Wenrong Liu, Yalan Yang, Ruofan Ding, Qingqing Huang, Junhua Meng, Lili Xiong*, Zhiyun Guo*. Identification and analysis of p53-mediated competing endogenous RNA network in human hepatocellular carcinoma. International Journal of Biological Sciences.2017, 13(9): 1213-1221.

12.   Wenrong Liu#, Ruofan Ding, Yiming Zhang, Canquan Mao, Ran Kang, Junhua Meng, Qingqing Huang, Lili Xiong, Zhiyun Guo*. Transcriptome profiling analysis of differentially expressed mRNAs and lncRNAs in HepG2 cells treated with peptide 9R-P201. Biotechnology Letters. 2017, doi: 10.1007/s10529-017-2407-1. 39(11):1639-1647

13.   Rao S#, Martínez-Cengotitabengoa M, Yao Y, Guo Z, Xu Q, Li S, Zhou X, Zhang F. Peripheral blood nerve growth factor levels in major psychiatric disorders. J Psychiatr Res. 2017, 86:39-45

14.   Yang Y#, Liu W, Ding R, Xiong L, Dou R, Zhang Y, Guo Z*. Comprehensive Expression Profiling and Functional Network Analysis of p53-Regulated MicroRNAs in HepG2 Cells Treated with Doxorubicin. PLoS One. 2016, 17;11(2):e0149227

15.   Lili Xiong, Ayyappa Kumar Sista Kameshwar, Xi Chen, Zhiyun Guo, Canquan Mao, Sanfeng Chen and Wensheng Qin*.The ACEII recombinant Trichoderma reesei QM9414 strains with enhanced xylanase production and its applications in production of xylitol from tree barks. Microb Cell Fact. 2016 Dec 28;15(1):215.

16.   Guo ZY#, Maki M, Ding RF, Yang YL, Zhang, B, Xiong, LL*. Genome-wide survey of tissue-specific microRNA and transcription factor regulatory networks in 12 tissues. Scientific Reports. 2014, 3(4): 5150

17.   Xiong LL#, Maki M, Guo ZY, Mao CQ, Qin WS: Agave biomass is excellent for production of bioethanol and xylitol using bacillus strain 65S3 and pseudomonas strain CDS3. J. Biobased Mater Bioenergy. 2014, 8: 422-428

18.   Xiong LL#, Jang W, Zhou R, Mao CQ, Guo ZY*. Identification and analysis of the regulatory network of Myc and microRNAs from high-throughput experimental data. Comput Biol Med. 2013, 43(9):1252-1260

19.   Wang XL#, Wang X, Xiong LL, Zhu Y, Chen HL, Wang XX, Li RL, Guo ZY, Li P, Jiang W*.: Salidroside improves Doxorubicin-induced cardiac dysfunction by suppression of excessive oxidative stress and cardiomyocyte apoptosis: Doxorubicin cardiotoxicity inhibited by salidroside. J. Cardiovascular Pharmacology 62(6): 512-523, 2013.

20.   Zhou R#, Huang WJ#, Guo ZY#, Li L, Tang M, Deng YQ, Li ZQ, Yang JY, Yang L, Tong AP*. Molecular mechanism of hepatocellular carcinoma-specific antitumor activity of novel thienopyridine derivative TP58. Oncology reports. 2012, 28(1):225-231.

21.   Tong XX#, Wu D, Wang X, Chen HL, Chen JX, Wang XX, Wang XL, Gan L, Guo ZY, Shi GX, Zhang YZ, Jiang W*. : Ghrelin protects against cobalt chloride-induced hypoxic injury in cardiac H9c2 cells by inhibiting oxidative stress and inducing autophagy. Peptides 38(2): 217-222, 2012.

22.   Gan L, Jiang W., Xiao YF, Deng L, Gu LD, Guo ZY, Zhou ZC, Wu D, Xin HB*.: Disruption of CD38 gene enhances cardiac functions by elevating serum testosterone in the male null mice. Life Sciences 89(13): 491-497, 2011.

23.   Chen DZ, Li P, Guo WH, Ye F, Wu J, Wei DM, Guo ZY, Ye C*.: Molecular evolution of candidate sour taste receptor gene PKD1L3 in mammals. Genome 54(11): 890-897, 2011.

24.   Xiong LL, Zhao P, Guo ZY, Zhang JH, Li DQ, Mao CQ*.: α -synuclein: Gene structure, evolution and in vitro protein aggregation. Neural Regeneration Research, 2010, 5(18): 1423-1428

 







教育经历

暂无内容

研究方向

更多+
  • 肿瘤生物信息与分子生物学
  • 抗肿瘤药物与肿瘤早期诊断
  • 基于高通量测序的精准医疗与健康大数据挖掘
  • 分子模拟与计算机辅助药物设计

招生信息

硕士研究生
学院 专业 研究方向 年份
生命科学与工程学院 生物学 2024
生命科学与工程学院 生物与医药 2024
生命科学与工程学院 药学 2024

说明:硕士招生专业是由导师本人填写的,可能有部分老师没有设置,但不代表不招收硕士。

团队成员

报考该导师研究生的方式

欢迎你报考郭志云老师的研究生,报考有以下方式:

1、参加西南交通大学暑期夏令营活动,提交导师意向时,选择郭志云老师,你的所有申请信息将发送给郭志云老师,老师看到后将和你取得联系,点击此处参加夏令营活动

2、如果你能获得所在学校的推免生资格,欢迎通过推免方式申请郭志云老师研究生,可以通过系统的推免生预报名系统提交申请,并选择意向导师为郭志云老师,老师看到信息后将和你取得联系,点击此处推免生预报名

3、参加全国硕士研究生统一招生考试报考郭志云老师招收的专业和方向,进入复试后提交导师意向时选择郭志云老师。

4、如果你有兴趣攻读郭志云老师博士研究生,可以通过申请考核或者统一招考等方式报考该导师博士研究生。